Tien Liang BioTech Co (ROCO:4127) Cyclically Adjusted Revenue per Share: NT$13.47 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4127 Tien Liang BioTech Co Ltd ROCO:4127
36 GF Score
Price NT$89.30
GF Value NT$45.55
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Tien Liang BioTech Co Cyclically Adjusted Revenue per Share?

Tien Liang BioTech Co ROCO:4127 +3.84% 36 Cyclically Adjusted Revenue per Share is NT$13.47 as of Mar. 2026. GuruFocus rates ROCO:4127 with a GF Score™ of 36/100 and a GF Value™ of NT$45.55 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Tien Liang BioTech Co's adjusted revenue per share for the three months ended in Mar. 2026 was NT$4.346. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$13.47 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Tien Liang BioTech Co's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -6.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Tien Liang BioTech Co was -1.50% per year. The lowest was -6.90% per year. And the median was -3.55% per year.

As of today (2026-08-10), Tien Liang BioTech Co's current stock price is NT$89.30. Tien Liang BioTech Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was NT$13.47. Tien Liang BioTech Co's Cyclically Adjusted PS Ratio of today is 6.63.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Tien Liang BioTech Co was 6.63. The lowest was 0.51. And the median was 0.87.


Tien Liang BioTech Co  (ROCO:4127) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Tien Liang BioTech Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=89.30/13.47
=6.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Tien Liang BioTech Co was 6.63. The lowest was 0.51. And the median was 0.87.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Tien Liang BioTech Co Cyclically Adjusted Revenue per Share Related Terms


Tien Liang BioTech Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Tien Liang BioTech Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tien Liang BioTech Co Cyclically Adjusted Revenue per Share Chart

Tien Liang BioTech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.78 16.63 15.56 14.41 13.41

Tien Liang BioTech Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.17 13.91 13.72 13.41 13.47

ROCO:4127 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Tien Liang BioTech Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tien Liang BioTech Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tien Liang BioTech Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Tien Liang BioTech Co's Cyclically Adjusted PS Ratio falls into.


ROCO:4127
36GF Score
Tien Liang BioTech Co Ltd ROCO:4127
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tien Liang BioTech Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Tien Liang BioTech Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=4.346/330.2130*330.2130
=4.346

Current CPI (Mar. 2026) = 330.2130.

Tien Liang BioTech Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 4.259 241.018 5.835
201609 3.822 241.428 5.228
201612 3.920 241.432 5.361
201703 3.681 243.801 4.986
201706 2.591 244.955 3.493
201709 2.128 246.819 2.847
201712 2.871 246.524 3.846
201803 2.733 249.554 3.616
201806 3.039 251.989 3.982
201809 2.655 252.439 3.473
201812 3.214 251.233 4.224
201903 2.427 254.202 3.153
201906 2.171 256.143 2.799
201909 2.077 256.759 2.671
201912 2.858 256.974 3.673
202003 2.643 258.115 3.381
202006 2.248 257.797 2.879
202009 2.108 260.280 2.674
202012 2.407 260.474 3.051
202103 2.468 264.877 3.077
202106 2.965 271.696 3.604
202109 3.458 274.310 4.163
202112 3.572 278.802 4.231
202203 3.264 287.504 3.749
202206 2.708 296.311 3.018
202209 2.685 296.808 2.987
202212 2.923 296.797 3.252
202303 2.733 301.836 2.990
202306 2.415 305.109 2.614
202309 2.263 307.789 2.428
202312 2.545 306.746 2.740
202403 2.576 312.332 2.723
202406 1.917 314.175 2.015
202409 2.076 315.301 2.174
202412 1.898 315.605 1.986
202503 2.581 319.799 2.665
202506 2.777 322.561 2.843
202509 2.972 324.800 3.022
202512 2.877 324.054 2.932
202603 4.346 330.213 4.346

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$13.47 mean?
Tien Liang BioTech Co (ROCO:4127) has a Cyclically Adjusted Revenue per Share of NT$13.47 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Tien Liang BioTech Co and its competitors.
Is Tien Liang BioTech Co's Cyclically Adjusted Revenue per Share too high?
Tien Liang BioTech Co's current Cyclically Adjusted Revenue per Share is NT$13.47. Overall, Tien Liang BioTech Co has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tien Liang BioTech Co's Cyclically Adjusted Revenue per Share compare to ZTS?
Tien Liang BioTech Co's Cyclically Adjusted Revenue per Share of NT$13.47 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Tien Liang BioTech Co and its competitors. Tien Liang BioTech Co's current Cyclically Adjusted Revenue per Share is NT$13.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tien Liang BioTech Co stock overvalued right now?
Based on GuruFocus' analysis, Tien Liang BioTech Co (ROCO:4127) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$45.55, compared to a current price of NT$89.30 — trading 96% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$13.47. Tien Liang BioTech Co's overall GF Score™ is 36/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Tien Liang BioTech Co (ROCO:4127), the current Cyclically Adjusted Revenue per Share is NT$13.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tien Liang BioTech Co (ROCO:4127) Overvalued in 2026?

Based on GuruFocus' analysis, Tien Liang BioTech Co stock appears to be overvalued. The current stock price of NT$89.30 is trading 96% above its estimated GF Value™ of NT$45.55. GuruFocus considers Tien Liang BioTech Co to be Significantly Overvalued.

Key valuation signals for ROCO:4127:

  • Cyclically Adjusted Revenue per Share: NT$13.47
  • GF Value™: NT$45.55 vs. price of NT$89.30 (96% above fair value)
  • GF Score™: 36/100 with 8 warning signs

No single metric tells the full story. See the ROCO:4127 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tien Liang BioTech Co Business Description

Address No. 147, Section 1, Datong Road, 9th Floor, Xizhi District, New Taipei City, TWN
Tien Liang BioTech Co Ltd develops and supplies chemicals, pharmaceutical, and Chinese herbs. It offers products for the treatment of intestinal track disease, osteoporosis, eye drops, cholesterin content, angiosclerosis, and hepatic diseases.
36GF Score

Get the complete analysis for ROCO:4127

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$89.30
Price
NT$45.55
GF Value